While Wall Street Naps, These 10 Stocks Run Wild

5. ImmunityBio, Inc. (NASDAQ:IBRX)

ImmunityBio grew its share price by 5.69 percent on Thursday to end at $2.6 apiece as investors continued to snap up shares following its expansion of the Cancer Bioshield Platform in the Middle East.

In a statement, ImmunityBio, Inc. (NASDAQ:IBRX) said it inked a memorandum of understanding with the Ministry of Investment of Saudi Arabia (MISA), King Faisal Specialist Hospital & Research Centre (KFSHRC), and King Abdullah International Medical Research Center (KAIMRC) for the adoption and introduction of the Cancer BioShield platform to Saudi Arabia and the broader Middle East.

The partnership will pave the way for a new era of immune-restorative therapies for cancer patients.

The BioShield platform, powered by its largest-revenue treatment, Anktiva, is expected to represent a paradigm shift in cancer care.

“We are honored to work with KAIMRC, KFSHRC, and MISA to bring this transformative technology to the region. The BioShield platform changes the way we think about treating cancer—not by destroying the immune system but by restoring and activating it,” said ImmunityBio, Inc. (NASDAQ:IBRX) Executive Chairman Patrick Soon-Shiong.